

3rd Meeting

European Myeloma Network Meeting



Virtual | April 6-9, 2022

FACULTY

Hervé Meral	Avet-Loiseau	Toulouse, France
Mario Niccolò	Beksac	Ankara, Turkey
Annemiek Michele	Boccadoro	Turin, Italy
Gordon Thomas	Bolli	Milan, Italy
Mattia Michel	Broijl	Rotterdam, The Netherlands
Meletios A. Isabelle	Cavo	Bologna, Italy
Brian G.M. Hermann	Cook	Leeds, United Kingdom
Thierry Carlos	Cupedo	Rotterdam, The Netherlands
Jaime Francesca	D'Agostino	Turin, Italy
Hartmut Roman	Delforge	Leuven, Belgium
Jean-Luc Graham	Dimopoulos	Athens, Greece
Martin Efstathios	Durand-Zaleski	Paris, France
Shaji Marc	Durie	North Hollywood, USA
Xavier Heinz	Einsele	Würzburg, Germany
Salomon Maria-Victoria	Facon	Lille, France
Roberto	Fernández de Larrea	Barcelona, Spain
	Gallego	Navarra, Spain
	Gay	Turin, Italy
	Goldschmidt	Heidelberg, Germany
	Hajek	Ostrava, Czech Republic
	Harousseau	Nantes, France
	Jackson	Newcastle upon Tyne, United Kingdom
	Kaiser	London, United Kingdom
	Kastritis	Athens, Greece
	Kumar	Rochester, USA
	Labetoulle	Paris, France
	Leleu	Poitiers, France
	Ludwig	Wien, Austria
	Manier	Lille, France
	Mateos	Salamanca, Spain
	Mina	Turin, Italy

Monique C. Philippe	Minnema	Utrecht, The Netherlands
Kate Nikhil C.	Moreau	Nantes, France
Enrique M. Stefania	Morgan	Edinburgh, United Kingdom
Bruno Giovanni	Munshi	Boston, USA
Charlotte Noemi	Ocio	Santander, Spain
Marc Jakub	Oliva	Turin, Italy
Noopur Karthik	Paiva	Pamplona, Spain
Leo Paula	Palladini	Pavia, Italy
Jesus Hans	Pawlyn	London, United Kingdom
Fredrik Hellem	Puig	Salamanca, Spain
Tobias Schmidt	Raab	Heidelberg, Germany
Pieter Evangelos	Radocha	Hradec Kralove, Czechia
Cyrille Carin	Raje	Boston, USA
Niels Marie	Ramasamy	Oxford, United Kingdom
Josephine M.I. Katja Christina	Rasche	Würzburg, Germany
Kwee Elena	Rodriguez Otero	Pamplona, Spagna
Sonja	San-Miguel	Navarra, Spain
	Scheurer	Brussels, Belgium
	Schjesvold	Oslo, Norway
	Slørdahl	Trondheim, Norway
	Sonneveld	Rotterdam, The Netherlands
	Terpos	Athens, Greece
	Touzeau	Nantes, France
	Uyl	Rotterdam, The Netherlands
	van de Donk	Amsterdam, The Netherlands
	Von Lilienfeld-Toal	Jena, Germany
	Vos	Amsterdam, The Netherlands
	Weisel	Hamburg, Germany
	Yong	London, United Kingdom
	Zamagni	Bologna, Italy
	Zweegman	Amsterdam, The Netherlands

WEDNESDAY, APRIL 6, 2022

14.00-14.15 **OPENING CEREMONY**

14.15-14.45 **SESSION I: CLINICAL STUDIES IN PROGRESS**

Chairpersons: H. Goldschmidt, T.S. Slørdahl

New studies under the EMN - **F. Gay**

National studies and collaborative trials in Europe - **C. Touzeau**

New studies in the USA - **S. Kumar**

15.00-15.30 **SESSION II: PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALK**

Chairpersons: B.G.M. Durie, H. Scheurer

MPE and patients in Europe - **H. Scheurer**

IMF and patients in the USA - **B.G.M. Durie**

15.45-16.30 **SESSION III: EMN-EHA joint session: Access to new treatments**

Chairpersons: I. Durand-Zaleski, H. Ludwig

Treatment access problems in the evolving treatment landscape:
the clinician's view - **J.L. Harousseau**

The Atlas initiative and how to improve access for patients - **K. Morgan**

Health economics & cost-effectiveness: how should drugs be paid for? - **C. Uyl**
Discussion

16.45-18.05 **SESSION IV: BEST ABSTRACTS - ORAL PRESENTATIONS**

Chairpersons: A. Broijl, F.H. Schjesvold

B01

STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT
IN MULTIPLE MYELOMA

M. de Jong, C. Fokkema, T. van Heusden, N. Papazian, S. Tahri, Z. Kellermayer, P. Vermeulen,
M. van Duin, P. van de Woestijne, A. Broijl, P. Sonneveld, T. Cupedo (*Rotterdam-NL*)

B02

REVERTING THE TUMOR-STROMAL METABOLIC COUPLING BY TARGETING LIPIDS RAFTS
DYNAMICS TO INCREASE SENSITIVITY TO BELANTAMAB MAFODITIN IN MULTIPLE MYELOMA
A. Romano, E. La Spina, D. Tibullo, C. Giallongo, G. Scandura, A. Barbato, F. Di Raimondo (*Catania-IT*)

B03

SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED
WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, A. Briasoulis, S. Gumeni, P. Malandrakis,
E-D. Papanagnou, M. Migkou, N. Kanellias, E. Kastritis, I. P. Trougakos, M. A. Dimopoulos (*Athens-GR*)

B04

COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

P. Rodriguez-Otero, B. Dholaria, E. Askari, D. Reece, N. van de Donk, A. Chari, H. Goldschmidt, A. Krishnan, T. Martin, M. Mateos, D. Morillo, C. Rodriguez, L. Rosinol, J. San-Miguel, A. Balari, R. Wäsch, K. Weisel, R. Verona, S. Lin, T. Prior, M. Wade, B. Weiss, J. Goldberg, A. Oriol, P. Hari (Navarra-ES, Nashville-USA, Madrid-ES, Toronto-CA, Amsterdam-NL, New York-USA, Heidelberg-DE, Duarte-USA, San Francisco-USA, Salamanca-ES, Winston-Salem-USA, Barcelona-ES, Freiburg-DE, Hamburg-DE, Spring House-USA, Raritan-USA, Milwaukee-USA)

B05

RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

F. Gay, J.G. Berdeja, V. De Stefano, P. Hari, B. Hooper, A. Haltner, S. Kumar, T. Martin, M.V. Mateos, P. Moreau, E. Rosta, I.A. Samjoo, S.Z. Usmani, K. Weisel, C.C. Jackson, Y. Olyslager, J.M. Schechter, M. Vogel, A. Garrett, S. Lee, T. Nesheiwat, L. Pacaud, C. Zhou, S. Valluri, L.J. Costa, Y. Lin (Torino, Nashville-USA, Roma, Milwaukee-USA, Sydney-CA, Rochester -USA), San Francisco-USA, Salamanca-ES, Nantes-FR, Burlington-CA, Charlotte-USA, Hamburg-DE, Raritan-USA, Beerse-BE, Piscataway-USA, Birmingham-USA)

B06

SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

M. Mateos, P. Hari, N. Bahlis, A. Chari, N.W.C.J. van de Donk, B. Dholaria, A.L. Garfall, H. Goldschmidt, K.M. Kortüm, A. Krishnan, T. Martin, D. Morillo, A. Oriol, D. Reece, C. Rodriguez, P. Rodríguez-Otero, J.F. San-Miguel, S.Z. Usmani, R. Verona, S.X.W. Lin, T.J. Prior, M. Wade, B. Weiss, J.D. Goldberg, E. Askari (Salamanca-ES, Milwaukee-USA, Calgary-CA, New York-USA, Amsterdam-NL, Nashville-USA, Philadelphia-USA, Heidelberg-DE, Würzburg-DE, Duarte-USA, San Francisco-USA, Madrid-ES, Badalona-ES, Toronto-CA, Winston-Salem-USA, Navarra-ES, Charlotte-USA, Spring House-USA, Raritan-USA)

B07

SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS

N.W.C.J. van de Donk, M. Delforge, M. Agha, A.D. Cohen, Y.C. Cohen, J. Hillengass, S. Anguille, T. Kerre, W. Roeloffzen, J.M. Schechter, K.C. De Braganca, H. Varsos, L. Wang, M. Vogel, E. Zudaire, C. Corsale, M. Akram, D. Geng, T. Nesheiwat, L. Pacaud, P. Sonneveld, S. Zweegman (Amsterdam-NL, Leuven-BE, Pittsburgh-USA, Philadelphia-USA, Tel Aviv-IL, Buffalo-USA, Edegem-BE, Ghent-BE, Groningen-NL, Raritan -USA, Spring House-USA, Piscataway-USA, Rotterdam-NL)

B08

A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

E. Terpos, M. Gavriatopoulou, I. Ntanas-Stathopoulos, A. Briasoulis, S.Gumeni, P. Malandrakis, E.D. Papanagnou, M. Migkou, N. Kanellias, E. Kastritis, I.P. Trougakos, M.A. Dimopoulos (Athens-GR)

THURSDAY, APRIL 7, 2022

13.40-14.10 **SESSION V: BIOLOGY**

Chairpersons: N.C. Munshi, N. Raje

Genetic evolution:

- From benign to malignant disease - **N. Bolli**
- Stromal and immune micro-environment - **T. Cupedo**
- Druggable MM therapeutics: Pathogenetic pathways - **E.M. Ocio**

14.20-15.50 **JANSSEN SPONSORED SYMPOSIUM**

Considerations for treatment sequencing in multiple myeloma: a roadmap to cure

Welcome and introduction - **S. Zweegman**

Current treatment strategies in patients with multiple myeloma - **P. Moreau**

Patient case discussion:

- Planning the patient journey for a transplant eligible patient with MM from front-line to fourth-line therapy - **S. Zweegman**
- Discussion
- Considerations for a transplant ineligible patient regarding treatment sequencing from front-line to fourth-line of therapy in multiple myeloma - **R. Mina**
- Discussion

16.00-16.50 **SESSION VI: HOW TO DEFINE HIGH-RISK MYELOMA ACCORDING TO NEW PROGNOSTIC FACTORS**

Chairpersons: J. San Miguel, P. Sonneveld

Cytogenetic risk factors: is it time for revision? Detection and impact of 1q & R2-ISS - **M. D'Agostino**

Emergence of high-risk clones - **H. Avet-Loiseau**

Circulating tumor cells - **B. Paiva**

Extramedullary disease - **M. Beksac**

Early relapse - **K. Yong**

17.00-18.30 **BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM**

Novel immunotherapies for advancing the treatment of multiple myeloma

Welcome and introduction - **T. Facon**

Evolving standard of care in NDMM and RRMM - **T. Facon**

Cellular therapies: a new era of treatment in MM - **M.V. Mateos**

Emerging immune therapies for RRMM: targets and modalities - **P. Rodriguez-Otero**

Emerging preclinical and clinical data for iberdomide and CC-92480 - **N. van de Donk**

Discussion

18.40-19.20 **SESSION VII: MRD IN MM**

Chairpersons: G. Jackson, B. Paiva

MRD in the bone marrow - **S. Oliva**

MRD in the peripheral blood: mass spec - **N. Puig**

MRD outside of the bone marrow: imaging - **E. Zamagni**

FRIDAY, APRIL 8, 2022

13.40- 14.40 **SESSION VIII: NEWLY DIAGNOSED MM**

Chairpersons: R. Hajek, X. Leleu

Transplant-eligible:

- Which induction therapy: where to aim for and when to switch - **P. Moreau**
- Upfront ASCT: does one size fits all? - **M. Cavo**
- Consolidation and maintenance - **P. Sonneveld**
- How to treat high risk patients - **M. Kaiser**

Non-Transplant-eligible:

- How to treat fit patients - **T. Facon**
- How to treat unfit and frail patients - **G. Cook**

14.50-16.20 **GSK SPONSORED SYMPOSIUM**

Future treatment and management of heavily pre-treated and refractory MM patients

Opening remarks: **M.V. Mateos**

Future combinations in heavily pre-treated and refractory MM patients - **E. Zamagni**

Improving patient's outcome through adverse events management

Focus on: Early recognition and management of corneal toxicity - **M. Labetoulle**

Focus on: Managing neurotoxicity - **J. Gallego**

Focus on: MM management in the context of COVID - **M. Von Lilienfeld-Toal**

Closing remarks - **M.V. Mateos**

16.30-17.00 **SESSION IX: TREATMENT AT RELAPSE**

Chairpersons: M. Boccadoro, M.A. Dimopoulos

What to do first - **M.V. Mateos**

How to sequence after first relapse - **C. Pawlyn**

How to treat triple class refractory myeloma - **P. Rodriguez-Otero**

17.10-18.40 **SANOFI SPONSORED SYMPOSIUM**

Climb every mountain: New routes to tackle in RRMM

Chairperson: A. Broijl

Introduction: State of the art treatment of high-risk patients in RRMM - **A. Broijl**

Finding the right path: Exploring the nuances of high-risk cytogenetics - **A. Broijl**

A challenging ascent: The impact of renal impairment - **M. Raab**

New peaks to explore: Considerations for frail and elderly patients - **S. Manier**

A changing view? The role of EMD in patients with RRMM - **E. Zamagni**

Discussion

18.50-19.20 **SESSION X: IMMUNETHERAPIES IN MM**

Chairpersons: H. Einsele, C. Fernández de Larrea

CAR-T cell therapies - **N. Raje**

Bispecific antibodies - **N. van de Donk**

How to choose & sequence immunotherapy - **N.C. Munshi**

SATURDAY, APRIL 9, 2022

- 9.00-9.30 **SESSION XI: AL AMYLOIDOSIS**
Chairpersons: M.C. Minnema, G. Palladini
Disease mechanisms & biomarkers - **G. Palladini**
Early diagnosis and optimal treatment - **E. Kastiris**
Light chain deposition disease - **J.M.I. Vos**
- 9.40-10.00 **SESSION XII: WHAT KIND OF TRIALS DO WE NEED IN THE FUTURE?**
Chairpersons: R. Mina, K.C. Weisel
Immunotherapy - **H. Einsele**
Elderly patients - **S. Zweegman**
- 10.15-10.45 **ADAPTIVE SPONSORED LECTURE**
Chairpersons: R. Mina, K.C. Weisel
Assessing Measurable Residual Disease in Multiple Myeloma patients
in Routine Clinical Practice - **K. Ramasamy**
- 11.00-11.30 **SESSION XIII: SIDE EFFECTS MANAGEMENT**
Chairpersons: J. Radocha, L. Rasche
Prophylaxis - **M. Delforge**
Covid-19 and myeloma - **H. Ludwig**
Bone disease - **E. Terpos**
- 11.30-11.45 **CONCLUSIONS AND FINAL GREETINGS**

POSTER

1. BIOLOGY AND PRECLINICAL

P01

ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY

A. Romano, G. Scandura, C. Giallongo, E. La Spina, A. Barbato, D. Tibullo, F. Di Raimondo (Catania)

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P02

PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS

G. Barilà, L. Bonaldi, A. Martines, A. Pascarella, S. Vedovato, C. Clissa, N. Macrì, A. Bonalumi, L. Pavan, M. Tinelli, S. Nalio, A. Teramo, G. Calabretto, V.R. Gasparini, M. Krampera, R. Bassan, R. Zambello (Venezia, Padova-IT)

P03

RATIONALE AND DEVELOPMENT OF AN E-HEALTH APPLICATION TO DELIVER PATIENT CENTERED CARE DURING TREATMENT FOR MULTIPLE MYELOMA IN THE NETHERLANDS

P. Geerts, J. Eijsink, A. Moser, P. ter Horst, C. Boersma, M. Postma (Zwolle-NL, Maastricht-NL, Heerlen-NL, Groningen-NL)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

P04

DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL

P. Sonneveld, A. Chanan-Khan, K. Weisel, A.K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.V. Mateos, T.M. Mark, M.D. Levin, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, A. Spencer (Rotterdam-NL, Jacksonville-FL, Hamburg-DE, Atlanta-GA, Budapest, Hungary-H, Ankara-TR, Prague-CS, São Paulo-BR, Mainz-DE, Salamanca, Spain-E, Aurora-CO, Dordrecht-NL, Plainsboro-NJ, Spring House-PA, Raritan-NJ, Beijing-RC, Melbourne-AUS)

P05

DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL

M.A. Dimopoulos, A. Oriol, H. Nahi, J. San-Miguel, N.J. Bahlis, S.Z. Usmani, N. Rabin, R.Z. Orłowski, K. Suzuki, T. Plesner, S.S. Yoon, D. Ben Yehuda, P.G. Richardson, H. Goldschmidt, D. Reece, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, P. Moreau (Athens-GR, Barcelona-ES, Stockholm-S, Pamplona-ES, Calgar-AB, New York-USA, London-UK, Houston-TX, Tokyo- J, Vejle-DK, Seoul-ROK, Jerusalem-IL, Boston-MA, Heidelberg-DE, Toronto-CDN, Plainsboro-NJ, Spring House-PA, Raritan-NJ, Beijing-RC, Nantes-FR)

P06
UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

R. Popat, S. Usman, A. Garfall, N. van de Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, P. Moreau, B. Besemer, J. Martínez-López, S. Sidana, L. Pei, D. Trancucci, R. Verona, S. Girgis, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan (*London-UK, Charlotte-USA, Philadelphia-USA, Amsterdam-NL, Stockholm-SE, Pamplona-ES, Barcelona-ES, Atlanta-USA, San Francisco-USA, New York-USA, Pierre-Bénite-FR, Tours-FR, Salamanca-ES, Calgary-CA, Nantes-FR, Tuebingen-DE, Madrid-ES, Palo Alto-USA, Raritan-USA, Spring House-USA, Antwerp-BE, Duarte-USA*)

P07
RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
N.W.C.J. van de Donk, R. Popat, C. Hulin, S. Jagannath, A. Oriol, P.G. Richardson, T. Facon, K. Weisel, J.T. Larsen, M. Minnema, A. Abdallah, A.Z. Badros, S. Knop, E.A. Stadtmauer, M. Chen, T.V. Nguyen, A. Amin, T. Peluso, S. Lonial (*Amsterdam-NL, London-UK, Pessac-FR, New York-USA, Badalona-ES, Boston-MA, Lille-FR, Hamburg-DE, Phoenix-AZ, Utrecht-NL, Kansas City-KS, Baltimore-MD, Würzburg-DE, Philadelphia-PA, Princeton-NJ, Boudry-CH, Atlanta-GA*)

P08
CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
H. Einsele, A.D. Cohen, M. Delforge, J. Hillengass, H. Goldschmidt, K. Weisel, M.-S. Raab, C. Scheid, J.M. Schechter, K.C. De Braganca, H. Varsos, T.-M. Yeh, L. Wang, M. Vogel, C. Corsale, M. Akram, L. Pacaud, T. Nesheiwat, M. Agha, Y.C. Cohen (*Würzburg-DE, Philadelphia-USA, Leuven-BE, Buffalo-USA, Heidelberg-DE, Hamburg-DE, Cologne-DE, Raritan-USA, Piscataway-USA, Pittsburgh-USA, Aviv-IL*)

P09
ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY

M.A. Benda, H. Ulmer, R. Weger, T. Winder, B. Hartmann, I. Strassl, S. Sormann, E. Willenbacher, W. Willenbacher (*Feldkirch-DE, Triesen-Liechtenstein-A, Innsbruck-A, Linz-A, Graz-A*)

P10
TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1

N.W.C.J. van de Donk, M.C. Minnema, J.G. Berdeja, A. Oriol, A. Krishnan, P. Rodríguez-Otero, E. Askari, M. Mateos, L.J. Costa, R. Verona, J. Ma, S. Girgis, S. Yang, B. W. Hilder, J. Russell, J.D. Goldberg, A. Chari (*Amsterdam-NL, Utrecht-NL, Nashville-USA, Badalona-ES, Duarte-USA, Navarra-ES, Madrid-ES, Salamanca-ES, Birmingham-USA, Spring House-USA, Raritan-USA, New York-USA*)

P11
IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS
H. Auner, S. Brown, K. Walker, J. Kendall, B. Dawkins, D. Meads, G. Morgan, M. Kaiser, M. Cook, S. Roberts, C. Parrish, G. Cook (*London-UK, Leeds-UK, New York-USA, Birmingham-UK*)

P12
TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE
M.-C. Vekemans, M. Delforge, S. Anguille, J. Depaus, N. Meuleman, A. Van de Velde, I. Vande Broek, D. Strens, S. Van Hoorenbeeck, E.J. Moorkens, J. Diels, F. Ghilotti, S. Dalhuisen, S. Vandervennet (*Brussels-BE, Leuven-BE, Antwerp-BE, Edegem-BE, Yvoir-BE, Liege-BE, Sint-Niklaas-BE, Grimbergen-BE, Beerse-BE, Cologno Monzese, Breda-NL*)

P13
CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
R. Papat, A. Badros, S. Kumar, P. Rodriguez-Otero, A. Cohen, S. Manier, P. Voorhees, F. Gay, R. Rifkin, T. Martin, A. Chari, K. Weisel, A. Farooq, B. Jeng, W. Chng, H. Lee, J. Berdeja, V. Jadhav, A. Tosolini, L. Eliason, A. Palumbo, M. Dimopoulos, S. Lonial, S. Trudel, P. Richardson, E. Terpos (*London-UK, Baltimore-USA, Rochester-USA, NavarraES, Philadelphia-USA, Lille-FR, Charlotte-USA, Torino, Steamboat Springs-USA, San Francisco-USA, New York-USA*), *Hamburg-DE, Chicago-USA, Singapore-J, Houston-USA, Nashville-US, Bengaluru-IND, Upper Providence-USA, Zug-CH, Athens-GR, Atlanta-USA, Toronto-CDN, Boston-USA*)

P14
DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
S. Usmani, A. Alonso, H. Quach, Y. Koh, A. Guenther, CK. Min, X. Leleu, AO. Abdallah, A. Oriol, B. Bessemer, M. Garg, I. Sandhu, K. Weisel, E. Ocio San Miguel, M. Cavo, X. Zhou, M. Kaisermann, L. Mis, D. Williams, A. Yeakey, G. Ferron-Brady, D. Figueroa, B. Kremer, I. Gupta, W. Janowski (*Charlotte-USA, Madrid-ES, Melbourne-AUS, Seoul-ROK, Schwerin-DE, Poitiers-FR, Kansas City-USA, Badalona-ES, Tübingen-DE, Leicester-UK, Edmonton-CDN, Hamburg-DE, Santander-ES, Bologna, Waltham-USA, Upper Providence-USA, Mississauga-CDN, Research Triangle Park-USA, Newcastle-AUS*)

P15
EVOLUTION OF MULTIPLE MYELOMA TREATMENT PATTERNS FROM 2015 THROUGH 2019: REAL-WORLD EVIDENCE FROM A EUROPEAN DATABASE STUDY
A. Oriol Rocafiguera T.H. Steinmetz, A. Brescianini, S. Gonzalez-McQuire, N. Eugene, A. Abbasi, S. Wetten, X. Leleu (*Badalona-ES, Barcelona-ES, Cologne-DE, Rotkreuz-CH, Uxbridge-UK, Poitiers-FR*)

P16
DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY
E. Terpos, I. Ntanasis-Stathopoulos, E. Kastritis, E. Hatjiharissi, E. Katodritou, E. Eleutherakis-Papaiakovou, E. Verrou, M. Gavriatopoulou, A. Leonidakis, S. Delimpasi, P. Malandrakis, M-C. Kyrtsonis, M. Papaioannou, A. Symeonidis, M.A. Dimopoulos (*Athens-GR, Thessaloniki-GR, Patras-GR*)

P17
DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza L. Melillo, V. Pavone, G. Tarantini, P. Curci, A.P. Falcone, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore (*Brindisi, San Giovanni Rotondo, Lecce, Bari, Taranto, Foggia, Tricase, Barletta*)

P18
DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza, L. Melillo, V. Pavone, G. Tarantini, P. Curci, A.P. Falcone, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore (*Brindisi, San Giovanni Rotondo, Lecce, Bari, Taranto, Foggia, Tricase, Barletta*)

P19
BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMMA TRIAL
P. Rodríguez-Otero, N. Shah, N. Munshi, J. Berdeja, S. Jagannath, O. Finney, N. Martin, A. Agarwal, E. Rowe, T. Campbell, J. San-Miguel (*Pamplona-ES, San Francisco-USA, Boston-USA, Nashville-USA, New York-USA, Cambridge-USA, Princeton-USA*)

P20
POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
R. Iula, F. Trastulli, R. Della Pepa, A. D’Ambrosio, M. Romano, A. Leone, G. Gaeta, S. Palmieri, S. Rocco, F. Pane, F. Ferrara, L. Catalano (*Napoli*)

P21
SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
P. Rodríguez-Otero, J. San-Miguel, L.D. Anderson Jr, S. Lonial, A. Truppel-Hartmann, J. Sanford, E. Rowe, T.B. Campbell, N. Munshi (*Pamplona-ES, Dallas-USA, Atlanta-USA, Cambridge-USA, Princeton-USA, Boston-USA*)

P22
A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS OF THE 'OL-ORAL' STUDY
E. Katodritou, M.C. Kyrtsonis, S. Delimpasi, E. Spanoudakis, G. Vassilopoulos, P. Zikos, N. Viniou, G. Kaiafa, M. Papathanasiou, V. Pappa, E. Michalis, I. Adamopoulos, K. Kokoviadou, G. Tsirakis, C. Poziopoulos, E. Terpos (*Thessaloniki-GR, Athens-GR, Alexandroupoli-GR, Larissa-GR, Patras-GR, Kalamata-GR, Chania-GR*)

P23
RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY
F. Fazio, A. Di Rocco, T. Za, V. Tomarchio, A. Rago, A. Piciocchi, T. Caravita di Toritto, O. Annibali, V. De Stefano, R. Foà, M. Martelli, M.T. Petrucci (*Roma*)

P24
EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE
M. Mateos, X. Leleu, E. Zamagni, M. Delforge, S. Bringhen, A. Broijl, J. de la Rubia, A. Shaw, A. Brescianini, S. Gonzalez-McQuire, S. Patel, P. Moreau (*Salamanca-ES, Poitiers-FR, Bologna, Leuven-BE, Torino, Rotterdam-NL, Valencia-ES, Oxford-UK, Rotkreuz-CH, Uxbridge-UK, Nantes-FR*)

4. SPECIAL CONDITIONS

P25
CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
S. Morè, V.M. Manieri, L. Corvatta, E. Morsia, S. Rupoli, A. Olivieri, M. Offidani (*Ancona, Fabriano*)

P26
EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
M. Brescini, F. Fazio, M.T. Petrucci (*Roma*)

P27
HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGHLY DEPENDENT TO BONE MARROW PLASMACYTOSIS: LONG FOLLOW-UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS
G. Mele, C. Romano, A. Spina, F. Merchionne, G. Quintana, M. Urbano, A.M. Pasanisi, E. Rinaldi, M.P. Solfrizzi, A. Romano, G. Guaragna, M.L. DiNoi, A. Miccoli, A. Santoro, D. Pastore (*Brindisi*)

P28
RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS
G. Cengiz Seval, E. Kircali, D. Koyun, B. Karakaya, H. Yilmaz, G. Yavuz, H. Akbulut, S.K. Toprak, P. Topcuoglu, O. Arslan, M. Ozcan, O. Ilhan, M. Beksac (*Ankara-TR*)

P29
EFFECTS OF VACCINATION ON INCIDENCE AND OUTCOME OF SARS-COV-2 INFECTION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
N. Sgherza, R. Rizzi, P. Curci, D. Roccotelli, M. Croce, M. Avantaggiato, L. Ruga, P. Musto (*Bari*)

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS

